Spyre Therapeutics Inc
SYREHealthcare|Biotechnology|USA
$97.74
-1.01 (-1.02%)
Tangible Book
$6.53
About
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Stock Price
+512.4%(1Y)
Pipeline Summary
7 total trials4
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Active: 3Recruiting: 2ENROLLING_BY_INVITATION: 1Completed: 1
Active Trials (5)
A Study of SPY003-207 in Healthy Volunteers
NCT06873724Healthy
Phase 1Active
Enrollment: 59 participants
A Study of SPY002-072 in Healthy Volunteers
NCT06622070Healthy
Phase 1Recruiting
Enrollment: 56 participants
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis
Phase 2Recruiting
Enrollment: 645 participants
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis
Phase 2Active
Enrollment: 285 participants
A Study of SPY002-091 in Healthy Volunteers
NCT06672718Healthy
Phase 1Active
Enrollment: 50 participants
BioScore
4.4/10
Cautious
Ownership
Recent Insider Trades
Turtle CameronSELL
2026-07-0115,000 shares @ $87.69
Burrows Scott LSELL
2026-07-017,500 shares @ $87.74
Sloan SheldonSELL
2026-07-018,334 shares @ $87.7
Burrows Scott LSELL
2026-06-2515,000 shares @ $87.13
Fairmount Healthcare Fund II L.P.SELL
2026-06-234,684,781 shares @ $85.31
Recent News
2026-07-13 11:32:20
2026-07-03 04:00:13
2026-06-24 15:02:03
2026-06-24 04:00:14
2026-06-23 14:09:04
Data last updated: Jul 13, 2026, 12:39 PM